Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV ... and molecules targeting the viral capsid, which results in inhibition ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

HBV=hepatitis B virus. HBVDR=HBV drug resistance ... 78 new classes of antiviral agents are in trials (eg, small interfering RNA, capsid assembly inhibitors, and immunotherapies). 79 In most cases, ...

including amendment to accelerate clinical development of Assembly Bio’s novel small molecule hepatitis D virus candidate ABI-6250— SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Hepatitis D virus (HDV) infects the liver and causes severe inflammation. According to WHO estimates, 12 million people ...